Skip To Main Content
Takeda UK Limited on Muck Rack

Takeda UK Limited

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Takeda UK

Contact Takeda UK, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments

|
By Ash Bullement, Takeda UK Limited
| link.springer.com
Key Points for Decision Makers 1 Introduction 1.1 Cost-Effectiveness Analysis in Oncology Cancer imposes a significant economic burden on society, which will continue to increase with the expanding and aging global population. In 2018, it was estimated that there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide [1]. By 2040, this is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths globally [1].
Open in Who Shared Issue with article?
See all 1 articles